{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:35:52Z","timestamp":1790361352200,"version":"4.1.0"},"reference-count":25,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antihistamines are used for the treatment of allergic rhinitis, allergic conjunctivitis, chronic spontaneous urticaria and atopic eczema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study the reports of adverse drug reactions (ADRs) in children using antihistamines to provide prescribers with an overview of the possible toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We studied ADRs in children reported to the Netherlands Pharmacovigilance Centre Lareb in the years 1991\u20132014, assessed the Naranjo score and, when possible, computed the reporting OR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serious ADRs included one death (malignant neuroleptic syndrome), cardiac arrhythmia (one case) and convulsions (three cases). Skin eruptions, headache and somnolence were the most frequently reported ADRs. Aggression and agitation were also reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Toxicity can occur with second-generation antihistamines. The main toxicity relates to skin eruptions and central nervous system problems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/archdischild-2015-310315","type":"journal-article","created":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T23:58:38Z","timestamp":1461023918000},"page":"968-970","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Adverse drug reactions of systemic antihistamines in children in the Netherlands"],"prefix":"10.1136","volume":"101","author":[{"given":"Tjalling W","family":"de Vries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,4,18]]},"reference":[{"key":"key-10.1136\/archdischild-2015-310315-1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/archdischild-2013-304446","article-title":"Antihistamine use in children","volume":"100","author":"Fitzsimons","year":"2015","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"key-10.1136\/archdischild-2015-310315-2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00002018-200124020-00003","article-title":"Safety of antihistamines in children","volume":"24","author":"Ten Eick","year":"2001","journal-title":"Drug Saf"},{"key":"key-10.1136\/archdischild-2015-310315-3","unstructured":"European Medicines Agency. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002749.pdf"},{"key":"key-10.1136\/archdischild-2015-310315-4","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJM200506233522522","article-title":"Boxed warning added to promethazine labeling for pediatric use","volume":"352","author":"Starke","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.1136\/archdischild-2015-310315-5","first-page":"1362","article-title":"Serious psychological side effect in children taking high doses of deptropine","volume":"136","author":"Stricker","year":"1992","journal-title":"Ned Tijdschr Geneeskd"},{"key":"key-10.1136\/archdischild-2015-310315-6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.1136\/archdischild-2015-310315-7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidem Drug Safe"},{"key":"key-10.1136\/archdischild-2015-310315-8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00431-002-0956-2","article-title":"Neuroleptic malignant syndrome in a 4-year-old girl associated with alimemazine","volume":"161","author":"van Maldegem","year":"2002","journal-title":"Eur J Pediatr"},{"key":"key-10.1136\/archdischild-2015-310315-9","unstructured":"Dutch Children's Formulary. http:\/\/www.kinderformularium.nl (accessed 28 Oct 2015)."},{"key":"key-10.1136\/archdischild-2015-310315-10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/157488610789869201","article-title":"Antihistamines: past answers and present questions","volume":"5","author":"Keller","year":"2010","journal-title":"Curr Drug Saf"},{"key":"key-10.1136\/archdischild-2015-310315-11","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0140-6736(99)01009-0","article-title":"QT lengthening and life-threatening arrhythmias associated with fexofenadine","volume":"353","author":"Pinto","year":"1999","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2015-310315-12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0033-1333871","article-title":"Seizures induced by desloratadine, a second-generation antihistamine: clinical observations","volume":"44","author":"Cerminara","year":"2013","journal-title":"Neuropediatrics"},{"key":"key-10.1136\/archdischild-2015-310315-13","first-page":"249","article-title":"(Des)loratadine en convulsies","volume":"110","author":"Passier","year":"2009","journal-title":"Tijdschr Neurol Neurochir"},{"key":"key-10.1136\/archdischild-2015-310315-14"},{"key":"key-10.1136\/archdischild-2015-310315-15","doi-asserted-by":"crossref","first-page":"22613","DOI":"10.5070\/D3205022613","article-title":"Cetirizine-induced acute generalized exanthematous pustulosis: a serious reaction to a commonly used drug","volume":"20","author":"Badawi","year":"2014","journal-title":"Dermatol Online J"},{"key":"key-10.1136\/archdischild-2015-310315-16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/106002809703100311","article-title":"Fixed drug eruption of the penis due to hydroxyzine hydrochloride","volume":"31","author":"Cohen","year":"1997","journal-title":"Ann Pharmacother"},{"key":"key-10.1136\/archdischild-2015-310315-17","first-page":"431","article-title":"Fixed drug eruption of the scrotum due to hydroxyzine hydrochloride (Atarax)","volume":"57","author":"Cohen","year":"1996","journal-title":"Cutis"},{"key":"key-10.1136\/archdischild-2015-310315-18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0301-0546(03)79199-X","article-title":"Fixed drug eruption due to loratadine","volume":"31","author":"Pionetti","year":"2003","journal-title":"Allergol Immunopathol"},{"key":"key-10.1136\/archdischild-2015-310315-19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaip.2013.09.011","article-title":"A pediatric case of chronic idiopathic urticaria induced by antihistamines","volume":"2","author":"Fung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.1136\/archdischild-2015-310315-20","doi-asserted-by":"crossref","first-page":"e1068","DOI":"10.1542\/peds.2013-0655","article-title":"Stabbing headache in an 8-year-old girl: primary or drug induced headache?","volume":"133","author":"Biedro\u0142","year":"2014","journal-title":"Pediatrics"},{"key":"key-10.1136\/archdischild-2015-310315-21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1399-3038.2007.00558.x","article-title":"Safety of levocetirizine treatment in young atopic children: an 18-month study","volume":"18","author":"Simons","year":"2007","journal-title":"Pediatr Allergy Immunol"},{"key":"key-10.1136\/archdischild-2015-310315-22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1081-1206(10)61208-2","article-title":"Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial","volume":"95","author":"Potter","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key-10.1136\/archdischild-2015-310315-23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1081-1206(10)60385-7","article-title":"Safety and tolerability of fexofenadine hydrochloride, 15 and 30\u2005mg, twice daily in children aged 6\u2005months to 2\u2005years with allergic rhinitis","volume":"99","author":"Hampel","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"key-10.1136\/archdischild-2015-310315-24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-3038.2005.00216.x","article-title":"Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial","volume":"16","author":"de Blic","year":"2005","journal-title":"Pediatr Allergy Immunol"},{"key":"key-10.1136\/archdischild-2015-310315-25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2015-310315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T14:00:41Z","timestamp":1692280841000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2015-310315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,18]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,9,19]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1136\/archdischild-2015-310315"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2015-310315","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,18]]}}}